GlassScriptPhysician profile
Kathryn Yagunic
NPI 1730664871
$3,137.23
in general payments reported to CMS, 2019-2025
32 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $859 · 2022: $997 · 2023: $956 · 2024: $150 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,281.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $377.97 | 2021-2023 | Jaypirca |
| Genentech USA, INC. | $275.82 | 2021-2023 | Lunsumio, Kadcyla, Perjeta |
| Seagen INC. | $259.58 | 2021-2023 | Adcetris, Padcev |
| Daiichi Sankyo INC. | $230.85 | 2021-2023 | Injectafer |
| Abbvie INC. | $225.17 | 2022-2024 | |
| Exelixis INC. | $174.91 | 2025 | |
| Pfizer INC. | $169.64 | 2021-2023 | |
| Gilead Sciences, INC. | $149.54 | 2021-2023 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $138.82 | 2022-2024 | Imfinzi |
| Adc Therapeutics America, INC. | $118.37 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $114.75 | 2023 | |
| Novartis Pharmaceuticals Corporation | $78.36 | 2021-2023 | Piqray |
| Genzyme Corporation | $77.78 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $69.20 | 2022-2023 | Xarelto |
| Coherus Oncology, INC. | $67.23 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $64.02 | 2022-2023 | Darzalex |
| Glaxosmithkline, LLC. | $61.63 | 2022-2023 | Zejula, Jemperli |
| Merck Sharp & Dohme LLC | $60.33 | 2022-2023 | Keytruda |
| Pharmacyclics LLC, An Abbvie Company | $59.97 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $50.50 | 2023 | Libtayo |
| Eisai INC. | $41.07 | 2022 | |
| Incyte Corporation | $40.83 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $35.61 | 2021 | |
| Lundbeck LLC | $30.48 | 2023 | Vyepti |
| G1 Therapeutics, INC. | $24.97 | 2023 | Cosela |
| Alexion Pharmaceuticals, INC. | $23.68 | 2022 | |
| Foundation Medicine, INC. | $21.76 | 2023 | Foundationone Liquid Cdx |
| Takeda Pharmaceuticals U.S.A., INC. | $21.39 | 2023 | Entyvio |
| Amag Pharmaceuticals, INC. | $20.96 | 2021 | |
| Celgene Corporation | $19.43 | 2021 | |
| Aurinia Pharma U.S., INC. | $18.48 | 2022 | |
| Calliditas Therapeutics US INC. | $14.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Yagunic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.